Article Information
History
- September 4, 2024.
Article Versions
- Version 1 (September 3, 2024 - 04:58).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- 1Institute of Frontier Science Initiative, Kanazawa University, Japan
- 2Central Research Resource Center, Cancer Research Institute, Kanazawa University,
- 3Institute of Biomedicine and MediCity Research Laboratories, University of Turku, Turku, Finland
- 4InFLAMES Research Flagship, University of Turku, Turku, Finland
- 5Turku Bioscience, University of Turku and Åbo Akademi University, Turku, Finland
- 6Department of Microbiology and Molecular Genetics, University of California, Davis, United States
- ↵*Corresponding author: skgothwal{at}staff.kanazawa-u.ac.jp & santoshgothwalbio{at}gmail.com
Posted September 04, 2024.
Distal super-enhancer drives aberrant CXCL13 expression in Cancer cells driving growth and p53 dysregulation via CXCR5-CXCL13 axis
